Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24074502 | 0.81 | TDP1 (0.36) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL18735658 | 0.81 | L3MBTL1 (0.39) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL31080044 | 0.81 | DGAT1 (0.45) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL1579422 | 0.80 | TDP1 (0.43) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL20125284 | 0.80 | TDP1 (0.43) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL18735657 | 0.80 | DGAT1 (0.48) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL13324201 | 0.79 | DGAT1 (0.46) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL487344 | 0.79 | DGAT1 (0.46) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL24191656 | 0.79 | DGAT1 (0.41) | CA12CA14CA1CA7DGAT1 | |
| SCHEMBL14182678 | 0.77 | MEN1 (0.41) | CA12CA14CA1CA7DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112759595-B | Method for synthesizing chiral acyclic nucleoside by asymmetric allylation reaction | 河南师范大学 | 2023-01-20 | — | — | CN | claimed |
| CN-112759595-A | Method for synthesizing chiral acyclic nucleoside by asymmetric allylation reaction | 河南师范大学 | 2021-05-07 | — | — | CN | claimed |
| WO-2024049976-A1 | N-METHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE COMPOUNDS | ABBVIE INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| CN-116438179-A | Pyrazole derivatives as RET kinase inhibitors | 伊莱利利公司 | 2023-07-14 | — | — | CN | disclosed |
| CN-112759595-B | Method for synthesizing chiral acyclic nucleoside by asymmetric allylation reaction | 河南师范大学 | 2023-01-20 | — | — | CN | disclosed |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-112759595-A | Method for synthesizing chiral acyclic nucleoside by asymmetric allylation reaction | 河南师范大学 | 2021-05-07 | — | — | CN | disclosed |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | BLADE THERAPEUTICS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10894776-B2 | — | — | 2021-01-19 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-9714261-B2 | Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
| WO-1997006161-A1 | ANTICOCCIDIAL 8-AMINOQUINOLINE DERIVATIVES | PFIZER LIMITED (GB) | 1997-02-20 | — | — | WO | disclosed |
| US-5356886-A | Treating herpes virus infections | BEECHAM GROUP P.L.C. (GB) | 1994-10-18 | — | — | US | disclosed |
| US-5270308-A | Hypotensives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-12-14 | — | — | US | disclosed |
| EP-0539487-A1 | ANTIVIRAL PHOSPHONO-ALKEN DERIVATIVES OF PURINES | BEECHAM GROUP PLC (GB) | 1993-05-05 | — | — | EP | disclosed |
| US-5108994-A | Synergistic with interferon; herpes virus | BEECHAM GROUP P.L.C. (GB) | 1992-04-28 | — | — | US | disclosed |
| EP-0477789-A1 | 1,3-Benzoxazine derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1992-04-01 | — | — | EP | disclosed |
| WO-1992001698-A1 | ANTIVIRAL PHOSPHONO-ALKEN DERIVATIVES OF PURINES | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | disclosed |
| EP-0399743-A1 | Phosphonomethylthio-alkoseypureine derivatives, intermediate products for their preparation and pharmaceutical compositions containing them | BEECHAM GROUP PLC (GB) | 1990-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | CA12 2102/4885CA14 2046/4885CA1 833/4885 |
| US-10934261-B2 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CA12 3546/4885CA14 3893/4885CA1 1624/4885 |
| US-10894776-B2 | — | CAPNS1, CAPN9, CAPN2 | CA12 4097/4885CA14 4351/4885CA1 2275/4885 |
| US-11339130-B1 | Calpain modulators and therapeutic uses thereof | CAPNS1, CAPN9, CAPN1 | CA12 3546/4885CA14 3893/4885CA1 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.